Literature DB >> 11034376

Effects of a constitutively active form of calcineurin on T cell activation and thymic selection.

K Hayden-Martinez1, L P Kane, S M Hedrick.   

Abstract

Calcineurin is a calcium/calmodulin-dependent phosphatase whose activity is required for the induction of T cell lymphokine production and proliferation. Although its specific role in T cell development is less well defined, studies with the immunosuppressive drugs cyclosporin A and FK-506 suggest that it is involved in both positive and negative selection of immature thymocytes. To more completely characterize a role for calcineurin in T cell development in vivo, we have generated transgenic mice that express an activated form of this enzyme in thymocytes and peripheral T cells. We find that the transgene causes a block in early thymic development, resulting in a reduction in the steady-state number of CD4 and CD8 double positives, but not on the number of mature T cells. We also find that thymocytes and mature T cells expressing this transgene are more sensitive to signals through their TCR. In thymocytes this sensitivity difference is manifested as an increase in positive selection, although negative selection seems to remain unaffected. Therefore, these studies confirm and extend past reports that suggested a role for calcineurin in thymic development and selection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11034376     DOI: 10.4049/jimmunol.165.7.3713

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

Review 1.  Transcriptional control of thymocyte positive selection.

Authors:  Gilbert J Kersh
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 2.  Transcription factors and target genes of pre-TCR signaling.

Authors:  Cristina López-Rodríguez; Jose Aramburu; Rosa Berga-Bolaños
Journal:  Cell Mol Life Sci       Date:  2015-02-22       Impact factor: 9.261

3.  Cyclosporine enhances the sensitivity to lenalidomide in MDS/AML in vitro.

Authors:  Xiaofei He; Aixia Dou; Saran Feng; Ashley Roman-Rivera; Caleb Hawkins; Lauren Lawley; Jiajia Zhang; Mark Wunderlich; Benjamin Mizukawa; Stephanie Halene; Amisha Patel; Jing Fang
Journal:  Exp Hematol       Date:  2020-05-08       Impact factor: 3.084

4.  Recruitment of calcineurin to the TCR positively regulates T cell activation.

Authors:  Debjani Dutta; Valarie A Barr; Itoro Akpan; Paul R Mittelstadt; Laishram I Singha; Lawrence E Samelson; Jonathan D Ashwell
Journal:  Nat Immunol       Date:  2016-12-12       Impact factor: 25.606

5.  Defective T cell development and function in calcineurin A beta -deficient mice.

Authors:  Orlando F Bueno; Eric B Brandt; Marc E Rothenberg; Jeffery D Molkentin
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-28       Impact factor: 11.205

6.  The importance of the Erk pathway in the development of linker for activation of T cells-mediated autoimmunity.

Authors:  Deirdre M Fuller; Minghua Zhu; Surapong Koonpaew; Mariana I Nelson; Weiguo Zhang
Journal:  J Immunol       Date:  2012-09-14       Impact factor: 5.422

Review 7.  The Role of Immune Checkpoint Receptors in Regulating Immune Reactivity in Lupus.

Authors:  Kun-Lin Lu; Ming-Ying Wu; Chi-Hui Wang; Chuang-Wei Wang; Shuen-Iu Hung; Wen-Hung Chung; Chun-Bing Chen
Journal:  Cells       Date:  2019-10-08       Impact factor: 6.600

8.  Low ligand requirement for deletion and lack of synapses in positive selection enforce the gauntlet of thymic T cell maturation.

Authors:  Peter J R Ebert; Lauren I Richie Ehrlich; Mark M Davis
Journal:  Immunity       Date:  2008-11-14       Impact factor: 31.745

9.  Presenilins regulate alphabeta T cell development by modulating TCR signaling.

Authors:  Karen Laky; B J Fowlkes
Journal:  J Exp Med       Date:  2007-08-13       Impact factor: 14.307

10.  TOX provides a link between calcineurin activation and CD8 lineage commitment.

Authors:  Parinaz Aliahmad; Emmett O'Flaherty; Peggy Han; Olivia D Goularte; Beverley Wilkinson; Masanobu Satake; Jeffery D Molkentin; Jonathan Kaye
Journal:  J Exp Med       Date:  2004-04-12       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.